Immune-related adverse events by immune checkpoint inhibitors.

@article{Kadono2017ImmunerelatedAE,
  title={Immune-related adverse events by immune checkpoint inhibitors.},
  author={Takafumi Kadono},
  journal={Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology},
  year={2017},
  volume={40 2},
  pages={83-89}
}
Recent introduction of immune checkpoint inhibitors represented by anti-PD-1 antibodies such as nivolumab and pembrolizumab, and anti-CTLA-4 antibody such as ipilimumab had a great impact on cancer immunotherapy especially for melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. On the other hand, immune checkpoint inhibitors have their own distinctive adverse events, which are collectively named as "immune-related adverse events". Although immune-related adverse… CONTINUE READING